Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Russell

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|April 4, 2017
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's diseaseC Warren Olanow, Karl Kieburtz, Mika Leinonen, et al.
Nature Neuroscience|December 5, 2006
IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiatesScott J Russo, Carlos A Bolanos, David E Theobald, et al.
Neurology|September 6, 2019
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trialMichael A Schwarzschild, Eric A Macklin, Rachit Bakshi, et al.
Nature Communications|October 27, 2023
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseasesRuben Smith, Francesca Capotosti, Martin Schain, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's diseaseWilliam Kielbasa, Paul Goldsmith, Kevin B Donnelly, et al.
Annals of Neurology|October 6, 2017
<sup>18</sup> F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter studyDaniel R Schonhaut, Corey T McMillan, Salvatore Spina, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2020
Early-phase [<sup>18</sup>F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injuryLeonie Beyer, Alexander Nitschmann, Henryk Barthel, et al.
JAMA Neurology|November 9, 2020
Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear PalsyMatthias Brendel, Henryk Barthel, Thilo van Eimeren, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|May 28, 2021
Binding characteristics of [<sup>18</sup>F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PETMengmeng Song, Leonie Beyer, Lena Kaiser, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Prasinezumab in Early-Stage Parkinson's DiseaseGennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Movement Disorders : Official Journal of the Movement Disorder Society|April 4, 2017
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's diseaseC Warren Olanow, Karl Kieburtz, Mika Leinonen, et al.
Nature Neuroscience|December 5, 2006
IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiatesScott J Russo, Carlos A Bolanos, David E Theobald, et al.
Neurology|September 6, 2019
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trialMichael A Schwarzschild, Eric A Macklin, Rachit Bakshi, et al.
Nature Communications|October 27, 2023
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseasesRuben Smith, Francesca Capotosti, Martin Schain, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's diseaseWilliam Kielbasa, Paul Goldsmith, Kevin B Donnelly, et al.
Annals of Neurology|October 6, 2017
<sup>18</sup> F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter studyDaniel R Schonhaut, Corey T McMillan, Salvatore Spina, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2020
Early-phase [<sup>18</sup>F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injuryLeonie Beyer, Alexander Nitschmann, Henryk Barthel, et al.
JAMA Neurology|November 9, 2020
Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear PalsyMatthias Brendel, Henryk Barthel, Thilo van Eimeren, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|May 28, 2021
Binding characteristics of [<sup>18</sup>F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PETMengmeng Song, Leonie Beyer, Lena Kaiser, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Prasinezumab in Early-Stage Parkinson's DiseaseGennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, et al.
Pageof 6